Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIZAR-005 study of GC101 tumor-infiltrating lymphocyte injection in advanced non-small cell lung cancer
CTR20261177Phase 2Active
- Sponsor
- Juncell Therapeutics
- Start
- Jul 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of nolgileucel in non-small cell lung cancer (NSCLC), sponsored by Juncell Therapeutics. Started Jul 2025; status: active.
02
Drugs
nolgileucel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261177.